Register for email alerts and news feeds:
This journal | BMJ Group
rss
Annals of the Rheumatic Diseases 2008;67:1787-1790; doi:10.1136/ard.2008.091900
Copyright © 2008 BMJ Publishing Group Ltd & European League Against Rheumatism.

Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor {alpha}

F Conti1, F Ceccarelli1, R Priori1, A Iagnocco1, A Signore2, G Valesini3

1 Dipartimento di Clinica e Terapia Medica, Sezione di Reumatologia, Sapienza Università di Roma, Policlinico Umberto I, Rome, Italy
2 Unità di Medicina Nucleare, II Facoltà di Medicina, Sapienza Università di Roma, Ospedale S. Andrea, Rome, Italy
3 Dipartimento di Clinica e Terapia Medica, Sezione di Reumatologia, Sapienza Università di Roma, Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy

Correspondence to:
Professor Guido Valesini, Dipartimento di Clinica e Terapia Medica, Sezione di Reumatologia, Sapienza Università di Roma, Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy; guido.valesini@uniroma1.it

Accepted 22 March 2008

The first 150 words of the full text of this article appear below.

Some experiences with intra-articular (IA) infliximab treatment in patients with refractory monoarthritis have been reported, even though these studies have important limitations including small sample size and short trial duration.14

Aim of this study was to evaluate the efficacy and safety of IA infliximab administration in a larger cohort of patients. We studied 10 patients with rheumatoid arthritis (RA) and seven with psoriatic arthritis (PsA) with active monoarthritis lasting at least 3 months, refractory to disease-modifying antirheumatic drugs (DMARDs) and to IA glucocorticoids.5 6 DMARDs dose had to be stable for at least 6 weeks before IA injection of infliximab, and it was maintained stable throughout the follow-up. IA methylprednisolone had to have been injected at least 6 weeks before the procedure. Concomitant treatment with anti-TNF{alpha} other than infliximab was permitted; indeed the biologic agent was stopped 2 weeks before and restarted 2 weeks after IA procedure. After removing synovial fluid, . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs